Skip to main content

Table 3 Per-patient and population level costs for the interventions included in the analysis

From: Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany

Patient-level

Treatment strategy

Added costs for a novel or group 5 intervention (€)

Cost of BR treatment

Hospitalization costs (€)

Outpatient care (€)

Monitoring costs (€)

Adverse event costs of group 5 drugs (€)

Total (€)

Bedaquiline plus BR

30,799

28,652

24,038

98

1970

17

85,575

Delamanid plus BR

22,829

29,626

26,362

108

2152

2

81,079

Linezolid plus BR

20,302

29,968

27,392

107

2569

121

80,460

BR only

0

30,270

28,180

119

2393

–

60,962

Population-level, 100 patients with MDR-TB

Bedaquiline plus BR

3,079,915

2,865,240

2,403,791

9833

197,014

1735

8,557,529

Delamanid plus BR

2,282,920

2,962,563

2,636,180

10,755

215,241

229

8,107,888

Linezolid plus BR

2,030,217

2,996,842

2,739,250

10,715

256,867

12,091

8,045,981

BR only

0

3,026,959

2,817,995

11,919

239,279

–

6,096,152

  1. AE adverse event, BR background regimen, TB tuberculosis, MDR-TB multidrug-resistant tuberculosis